Author:
Redfern Will S.,Valentin Jean-Pierre
Publisher
Springer Berlin Heidelberg
Reference55 articles.
1. Aiba A, Nakao H (2007) Conditional mutant mice using tetracycline-controlled gene expression system in the brain. Neurosci Res 58:113–117
2. Anon (2001) ICH S7A: safety pharmacology studies for human pharmaceuticals. Available at:
http://www.ich.org/cache/compo/276-254-1.html
3. Anon (2009) ICH M3(R2): guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Available at:
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf
4. Bailey KR, Rustay NR, Crawley JN (2006) Behavioral phenotyping of transgenic and knockout mice: practical concerns and potential pitfalls. ILAR J 47:124–131
5. Banfor PN, Mittelstadt S, Amberg W, Behl B, Kempf-Grote A, Lange U, Larsen M, Marsh K, Ochse M, Sydor J, Vogg B, King A (2011) Use of drug efflux transporter knockout mice to differentiate peripheral from centrally-mediated cardiovascular effects. J Pharmacol Toxicol Methods 64:e52